StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Gilead Sciences (GILD) Remdesivir China Results 'Very Sobering' - Baird
April 23, 2020 1:34 PM
Baird analyst Brian Skorney weighed in on Gilead Sciences (NASDAQ: GILD) related to news that a China trial of severe ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
Next Articles
WHO China Data Likely to Drive View that Gilead (GILD) Remdesivir Isn't Working in Severe Patients - Raymond James
April 23, 2020 2:00 PM
Gilead Sciences (GILD) China Trial Results 'In Line with our Expectations' - RBC
April 23, 2020 1:40 PM
SunTrust Said Need to See Gilead Sciences (GILD) Controlled Data on Remdesivir
April 23, 2020 1:32 PM
Gilead Sciences (GILD) call put ratio 2.3 calls to 1 put after FT says remdesivir failed in first trial
April 23, 2020 1:03 PM
Gilead Sciences (GILD) said post included inappropriate characterization of the study - STAT, citing Spokesperson
April 23, 2020 12:56 PM
Gilead Sciences (GILD) Resumes; Shares Down 2.5%
April 23, 2020 12:53 PM
Gilead Sciences (GILD) call put ratio 1 call to 1 put, FT says remdesivir failed in first trial
April 23, 2020 12:51 PM
Gilead Sciences (GILD) Halted on LUDP
April 23, 2020 12:46 PM
Gilead Sciences' (GILD) Antiviral Drug Remdesivir Flops in First trial - FT
April 23, 2020 12:45 PM
Gilead Sciences (GILD) April weeky calls active on open
April 23, 2020 9:34 AM
S&P 500 slips after report on coronavirus drug trial
April 23, 2020 7:12 AM
